Skip to main content
Premium Trial:

Request an Annual Quote

Orchid to Raise $14M in Private Placement

NEW YORK (GenomeWeb News) - DNA testing company Orchid Cellmark has struck agreements with new and existing institutional investors to raise around $14 million in private equity financing, the company said today.
 
Orchid said it plans to issue 4.87 million shares of stock at $2.88 each and that it expects the transaction to close today.
 
It plans to use the funding for working capital and general corporate expenses.
 
Orchid shares fell 6 percent on the news to $3.20 in afternoon trading.
 
Earlier this month, Orchid reported stagnant third-quarter revenues accompanied by narrowed net losses. The company had around $12.5 million in cash and cash equivalents as of Sept. 30.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.